Logo image of SYRA

SYRA HEALTH CORP - CLASS A (SYRA) Stock Fundamental Analysis

USA - NASDAQ:SYRA - US87168W2035 - Common Stock

0.1043 USD
-0.02 (-17.94%)
Last: 4/17/2025, 8:00:00 PM
0.0805 USD
-0.02 (-22.82%)
After Hours: 4/17/2025, 8:00:00 PM
Fundamental Rating

2

Overall SYRA gets a fundamental rating of 2 out of 10. We evaluated SYRA against 101 industry peers in the Health Care Providers & Services industry. SYRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SYRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SYRA had negative earnings in the past year.
SYRA had a negative operating cash flow in the past year.
SYRA had negative earnings in each of the past 5 years.
In the past 5 years SYRA always reported negative operating cash flow.
SYRA Yearly Net Income VS EBIT VS OCF VS FCFSYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

SYRA's Return On Assets of -102.17% is on the low side compared to the rest of the industry. SYRA is outperformed by 94.29% of its industry peers.
SYRA has a Return On Equity of -130.59%. This is amonst the worse of the industry: SYRA underperforms 80.95% of its industry peers.
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROIC N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SYRA Yearly ROA, ROE, ROICSYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

SYRA has a Gross Margin (20.71%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SYRA has declined.
SYRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
SYRA Yearly Profit, Operating, Gross MarginsSYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

4

2. Health

2.1 Basic Checks

SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SYRA has more shares outstanding
SYRA has a worse debt/assets ratio than last year.
SYRA Yearly Shares OutstandingSYRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly Total Debt VS Total AssetsSYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

Based on the Altman-Z score of -2.79, we must say that SYRA is in the distress zone and has some risk of bankruptcy.
SYRA has a worse Altman-Z score (-2.79) than 85.71% of its industry peers.
SYRA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
SYRA has a better Debt to Equity ratio (0.05) than 78.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC8.73%
SYRA Yearly LT Debt VS Equity VS FCFSYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
SYRA has a better Current ratio (5.46) than 95.24% of its industry peers.
SYRA has a Quick Ratio of 5.46. This indicates that SYRA is financially healthy and has no problem in meeting its short term obligations.
SYRA has a Quick ratio of 5.46. This is amongst the best in the industry. SYRA outperforms 95.24% of its industry peers.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 5.46
SYRA Yearly Current Assets VS Current LiabilitesSYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SYRA have decreased by -8.98% in the last year.
The Revenue has grown by 44.67% in the past year. This is a very strong growth!
The Revenue has been growing by 78.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYRA Yearly Revenue VS EstimatesSYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly EPS VS EstimatesSYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SYRA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRA Price Earnings VS Forward Price EarningsSYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRA Per share dataSYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SYRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYRA HEALTH CORP - CLASS A

NASDAQ:SYRA (4/17/2025, 8:00:00 PM)

After market: 0.0805 -0.02 (-22.82%)

0.1043

-0.02 (-17.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners6.21%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change0%
Market Cap1.18M
Revenue(TTM)7.98M
Net Income(TTM)-3759300
AnalystsN/A
Price Target1.84 (1664.14%)
Short Float %0.87%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)10.93%
Revenue beat(4)3
Avg Revenue beat(4)9.8%
Min Revenue beat(4)-2.21%
Max Revenue beat(4)22.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.71
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.71%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
F-Score4
Asset Turnover2.17
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.7%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.46
Quick Ratio 5.46
Altman-Z -2.79
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)287.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.27%
OCF growth 3YN/A
OCF growth 5YN/A

SYRA HEALTH CORP - CLASS A / SYRA FAQ

What is the ChartMill fundamental rating of SYRA HEALTH CORP - CLASS A (SYRA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SYRA.


What is the valuation status for SYRA stock?

ChartMill assigns a valuation rating of 0 / 10 to SYRA HEALTH CORP - CLASS A (SYRA). This can be considered as Overvalued.


How profitable is SYRA HEALTH CORP - CLASS A (SYRA) stock?

SYRA HEALTH CORP - CLASS A (SYRA) has a profitability rating of 0 / 10.